OR WAIT 15 SECS
Novasep's new antibody drug conjugate facility at its site in Le Mans, France will be commissioned in 2016.
Novasep will build a fully integrated antibody drug conjugate (ADC) facility at its Le Mans site in France, the company announced June 25, 2015. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The facility, scheduled to be commissioned in the second quarter of 2016, will provide contract manufacturing in batch sizes from a few milligrams to 600 g for clinical trials and commercial development.
“Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances," said said Thierry Van Nieuwenhove, president of Novasep’s Synthesis business unit, in a press release. "By integrating our R&D, analytical, and manufacturing services within a single unit, we can give customers flexibility, assurance of supply, and continuity in supply chains.”
Novasep’s €10M (USD 11.2 million) investment in clinical and commercial-scale ADC conjugation is a natural extension to its existing CMO offering and leverages its unique purification technologies.
“This move is part of our “back-to-basics” strategy, forging Novasep’s refocus on growing core businesses,” said Michel Spagnol, chairman and CEO of Novasep, in a press release.